IDEXX Laboratories with a clear strategy focus, shares anchored in the NASDAQ-100

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-29, 10:51.

IDEXX Laboratories (US45168D1046) builds its equity story on long-term growth in pet diagnostics and veterinary software. The NASDAQ-100 listing on NASDAQ provides global visibility and places the company alongside large-cap health and technology peers.

How IDEXX earns its money

IDEXX Laboratories reports three major operating pillars: Companion Animal Group diagnostics, water testing and livestock, poultry and dairy solutions, all supported by software and digital services. According to its investor materials, recurring consumables and lab services represent the majority of revenue and cash flow.IDEXX investor relations overview

Companion Animal Group includes in-clinic instruments, reference laboratory services and rapid assays used by veterinary practices for routine testing. The company highlights stable demand for wellness diagnostics and chronic disease monitoring, which supports a long-term growth profile in this segment.Business segment description

Long-term strategy and moat

IDEXX Laboratories emphasizes a strategy built on installed base expansion and deeper test utilization per patient visit rather than pure price increases. Management describes a focus on innovation in diagnostic assays and integration with practice management software to keep customers locked into the ecosystem.Recent management presentation

Analyst consensus compiled by MarketScreener shows an average 12-month price target of around 709.14 US dollars for the IDEXX shares, with several houses including Jefferies and Rothschild & Co Redburn maintaining positive long-term views on the diagnostics model.MarketScreener consensus snapshot

The product behind the stock

One core commercial product line at IDEXX Laboratories is the Catalyst chemistry analyzer platform used in veterinary clinics for in-house blood work. The analyzers run proprietary reagent clips, creating recurring consumables revenue tied to each test. This hardware-plus-consumables model underpins the company's long-term cash generation.

Where the stock trades today

The IDEXX Laboratories shares (US45168D1046) trade on NASDAQ at around 551.50 US dollars as of 2026-05-26, according to MarketScreener data, with the listing also represented in euro on German trading venues such as Tradegate.

This article provides a factual overview of the IDEXX Laboratories shares and business model. It does not constitute investment advice or a recommendation to buy or sell securities. Investors should consult professional advisors and original sources before making decisions.